Cerner and Elligo to Make Clinical Trials Accessible for Health Systems of All Sizes
December 08 2020 - 9:00AM
Cerner Corporation (NASDAQ: CERN), a global health care technology
company, today announced an investment in Elligo Health Research, a
leading integrated research organization that enables clinical
trials with nationwide community-based health care practices.
Cerner representatives will also join Elligo’s board of directors.
As a result of this investment, Cerner plans to enter into a
commercial agreement to expand the data and tools available in the
Cerner Learning Health Network to offer additional clinical trial
resources to community and rural hospitals and physician practices.
This collaboration is expected to help accelerate clinical research
timeframes, make clinical trials more broadly and easily accessible
and reduce the costs associated with bringing a therapy to market.
“At the beginning of the year, we launched a bold push with our
provider clients to change the pace and cost of clinical
trials. Today, 51 health systems are part of our Learning
Health Network,” said Donald Trigg, president, Cerner. “Elligo
shares our passion for making clinical trial opportunities
accessible to every provider and patient. Our collaboration
will accelerate that shared mission in the quarters ahead.”
Health systems face significant obstacles such as patient
recruitment, costs and access to clinical trial resources. Today,
for example, the drug development process takes more than 17 years
and costs approximately $2.5B. Cerner and Elligo will focus on
helping reduce those obstacles health systems face to make clinical
trials become more of a reality – no matter the size, location or
academic standing.
Additionally, most clinical trials are executed in large, urban
areas with homogenous trial populations, which offer insights that
may not be broadly applicable to all patients in need of the
therapies. Clinical trial resources can offer funded research
opportunities for health care organizations as well as access to
trial therapies for patients who need it most, including those in
minority populations and rural communities. This could result in
outcomes that are more representative of diverse populations and a
potential increase in drug safety through post-market surveillance
capabilities.
As one of the largest health networks for clinical research,
Elligo works to bring research as a care option to as many
participants as possible by offering innovative, patient-centric
solutions within the practices of trusted physicians.
“Elligo’s mission is to bring clinical research to everyone, but
today’s clinical research processes are obsolete and expensive,”
said John Potthoff, Ph.D., CEO, Elligo. “Our collaboration with
Cerner will be designed to help transform the research process by
optimizing operations, focusing on the patient and producing the
regulatory-grade data needed to inform decision-making.”
Financial terms were not disclosed.
Perella Weinberg Partners served as exclusive
financial advisor to Elligo and Goodwin Procter LLP served as legal
counsel to Elligo in connection with the investment. Stinson served
as legal counsel for Cerner.
About Cerner
Cerner’s health technologies connect people and
information systems at thousands of contracted provider facilities
worldwide dedicated to creating smarter and better care for
individuals and communities. Recognized globally for innovation,
Cerner assists clinicians in making care decisions and assists
organizations in managing the health of their populations. The
company also offers an integrated clinical and financial system to
help manage day-to-day revenue functions, as well as a wide range
of services to support clinical, financial and operational needs,
focused on people. For more information,
visit Cerner.com, The Cerner Blog or connect
on Facebook, Instagram, LinkedIn, Twitter or The
Cerner Podcast. Nasdaq: CERN. Health care is too
important to stay the same.
About Elligo Health Research
Elligo Health Research, a healthcare-enabling research
organization, uses electronic health records and the trusted
patient and physician relationship to ensure all patients have
access to clinical research as a care option. Powered by our Goes
Direct® approach and novel IntElligo® Research Stack clinical
technology, our team provides access to the best healthcare
experts, patients, and research technologies. We engage physicians
and patients who otherwise would not participate in clinical
research and accelerate the development of new pharmaceutical,
biotechnology, and medical device and diagnostic products. Learn
more at elligodirect.com.
Media Contacts:
Stephanie Greenwood, Cerner Public Relations,
stephanie.greenwood@cerner.com
Jane Byram, Elligo - SCORR Marketing, (512) 626-2758,
jane@scorrmarketing.com
Cerner (NASDAQ:CERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cerner (NASDAQ:CERN)
Historical Stock Chart
From Apr 2023 to Apr 2024